Acasti Pharma Inc. (NASDAQ:ACST – Get Free Report)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.74 and traded as high as $2.93. Acasti Pharma shares last traded at $2.93, with a volume of 2,465 shares changing hands.
Analyst Ratings Changes
Separately, Craig Hallum initiated coverage on shares of Acasti Pharma in a research note on Wednesday, February 7th. They issued a “buy” rating and a $6.00 target price for the company.
View Our Latest Stock Analysis on Acasti Pharma
Acasti Pharma Stock Down 1.0 %
Acasti Pharma (NASDAQ:ACST – Get Free Report) last issued its quarterly earnings data on Monday, February 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Equities analysts predict that Acasti Pharma Inc. will post -1.44 earnings per share for the current fiscal year.
Acasti Pharma Company Profile
Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Featured Articles
- Five stocks we like better than Acasti Pharma
- What is the S&P 500 and How It is Distinct from Other Indexes
- MarketBeat Week in Review – 4/22 – 4/26
- How to Choose Top Rated Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- CD Calculator: Certificate of Deposit Calculator
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Acasti Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acasti Pharma and related companies with MarketBeat.com's FREE daily email newsletter.